Literature DB >> 19117991

K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse.

Helen B Pearson1, Toby J Phesse, Alan R Clarke.   

Abstract

Aberrant Ras and Wnt signaling are emerging as key events in the multistep nature of prostate tumorigenesis and progression. Here, we report the generation of a compound model of prostate cancer to define the synergism of activated K-ras (K-ras(+/V12)) and dominant stabilized beta-catenin (Catnb(+/lox(ex3))) in the murine prostate. Recombination of floxed alleles and subsequent expression of oncogenic transgenes was mediated by Cre recombinase expression governed by the composite Probasin (PB) promoter (termed PBCre). Concomitant with elevated mitogen-activated protein kinase (MAPK) signaling, PBCre(+)K-ras(+/V12) mice developed AH at 100 days (100% incidence) and low-grade prostate intraepithelial neoplasia and adenocarcinoma (60% and 7% incidence) by 500 days. PBCre(+)Catnb(+/lox(ex3)) mice showed reduced longevity (average 428 days) and were predisposed to PIN-like keratinized squamous metaplasia at 100 days (100% incidence) and adenocarcinoma (100% incidence) at end-point. These lesions displayed elevated Wnt signaling and basal levels of MAPK signaling. Synchronous activation of K-ras and beta-catenin significantly reduced survival (average 189 days), reflecting accelerated tumorigenesis and the development of invasive carcinoma that displayed activated Wnt and MAPK signaling. Notably, expression of the basal cell marker p63 negatively correlated with tumor grade, resembling human prostate adenocarcinoma. Taken together, our data show that combinatorial oncogenic mutations of K-ras and beta-catenin drive rapid progression of prostate tumorigenesis to invasive carcinoma, characterized by the synergistic elevation of androgen receptor, cyclooxygenase-2, and c-Myc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19117991     DOI: 10.1158/0008-5472.CAN-08-2895

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice.

Authors:  Vanessa Fritz; Zohra Benfodda; Geneviève Rodier; Corinne Henriquet; François Iborra; Christophe Avancès; Yves Allory; Alexandre de la Taille; Stéphane Culine; Hubert Blancou; Jean Paul Cristol; Françoise Michel; Claude Sardet; Lluis Fajas
Journal:  Mol Cancer Ther       Date:  2010-06-08       Impact factor: 6.261

2.  PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.

Authors:  Matthew T Jefferies; Adam C Cox; Boris Y Shorning; Valerie Meniel; David Griffiths; Howard G Kynaston; Matthew J Smalley; Alan R Clarke
Journal:  J Pathol       Date:  2017-11-14       Impact factor: 7.996

3.  Wnt signaling in castration-resistant prostate cancer: implications for therapy.

Authors:  Noriko N Yokoyama; Shujuan Shao; Bang H Hoang; Dan Mercola; Xiaolin Zi
Journal:  Am J Clin Exp Urol       Date:  2014-04-15

4.  The Ras effector RASSF2 controls the PAR-4 tumor suppressor.

Authors:  Howard Donninger; Luke Hesson; Michele Vos; Kristin Beebe; Laura Gordon; David Sidransky; Jun Wei Liu; Thomas Schlegel; Shannon Payne; Arndt Hartmann; Farida Latif; Geoffrey J Clark
Journal:  Mol Cell Biol       Date:  2010-04-05       Impact factor: 4.272

Review 5.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

6.  Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis.

Authors:  Jeffrey C Francis; Afshan McCarthy; Martin K Thomsen; Alan Ashworth; Amanda Swain
Journal:  PLoS Genet       Date:  2010-06-24       Impact factor: 5.917

7.  beta-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor.

Authors:  Udi Gluschnaider; Guy Hidas; Gady Cojocaru; Vladimir Yutkin; Yinon Ben-Neriah; Eli Pikarsky
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

Review 8.  Genetically engineered mouse models of prostate cancer.

Authors:  Maxime Parisotto; Daniel Metzger
Journal:  Mol Oncol       Date:  2013-02-14       Impact factor: 6.603

9.  Sprouty genes function in suppression of prostate tumorigenesis.

Authors:  Jennifer L Schutzman; Gail R Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-13       Impact factor: 11.205

Review 10.  Genetically modified laboratory mice with sebaceous glands abnormalities.

Authors:  Carmen Ehrmann; Marlon R Schneider
Journal:  Cell Mol Life Sci       Date:  2016-07-25       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.